We are live on ! Find out more
VCIM

Velan Capital Investment Management Portfolio holdings

AUM $160M
1-Year Est. Return 517.12%
This Fund
S&P 500
This Quarter Est. Return
+20.24%
1 Year Est. Return
+517.12%
3 Year Est. Return
+2,524.89%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$160M
AUM Growth
-$12.7M
Cap. Flow
-$14.4M
Cap. Flow %
-9.01%
Top 10 Hldgs %
73.06%
Holding
57
New
11
Increased
13
Reduced
7
Closed
8

Top Buys

Rank Stock Value
1
TENX icon
Tenax Therapeutics
TENX
+$6.76M
2
IMMX icon
Immix Biopharma
IMMX
+$5.18M
3
AVR
Anteris Technologies
AVR
+$4.02M
4
STRO icon
Sutro Biopharma
STRO
+$3.62M
5
XNCR icon
Xencor
XNCR
+$3.1M

Top Sells

Rank Stock Value
1
CDTX
Cidara Therapeutics
CDTX
+$23.9M
2
LNTH icon
Lantheus
LNTH
+$4.97M
3
MLYS icon
Mineralys Therapeutics
MLYS
+$4.11M
4
RAPT
RAPT Therapeutics
RAPT
+$3.66M
5
TERN
Terns Pharmaceuticals
TERN
+$2.83M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRAX icon
1
Praxis Precision Medicines
PRAX
$8.49B
$32.5M 20.34%
100,781
– –
TARA icon
2
Protara Therapeutics
TARA
$229M
$14.8M 9.25%
2,834,652
– –
STRO icon
3
Sutro Biopharma
STRO
$374M
$12.8M 7.99%
512,160
+200,160
+64% +$3.62M
EVMN
4
Evommune Inc
EVMN
$415M
$10.3M 6.43%
446,255
-60,499
-12% -$1.37M
MPLT
5
MapLight Therapeutics
MPLT
$1.63B
$10M 6.28%
492,893
-29,412
-6% -$526K
TENX icon
6
Tenax Therapeutics
TENX
$416M
$9.33M 5.84%
583,333
+500,000
+600% +$6.76M
ABVX
7
Abivax
ABVX
$11.5B
$8.57M 5.37%
77,000
+10,000
+15% +$1.18M
HRTX icon
8
Heron Therapeutics
HRTX
$90.9M
$7M 4.39%
8,753,290
– –
IMMX icon
9
Immix Biopharma
IMMX
$626M
$6.74M 4.22%
740,000
+705,000
+2,014% +$5.18M
ESPR
10
DELISTED
Esperion Therapeutics
ESPR
$4.71M 2.95%
1,720,000
+510,000
+42% +$1.61M
EDSA icon
11
Edesa Biotech
EDSA
$56.1M
$4.33M 2.71%
827,500
+140,000
+20% +$420K
AVR
12
Anteris Technologies
AVR
$800M
$3.88M 2.43%
+700,000
New +$4.02M
NSPR icon
13
InspireMD
NSPR
$33M
$3.42M 2.14%
2,099,652
-44,046
-2% -$75.1K
XNCR icon
14
Xencor
XNCR
$1.39B
$3.02M 1.89%
+250,000
New +$3.1M
AVTX icon
15
Avalo Therapeutics
AVTX
$957M
$2.76M 1.73%
185,122
-78,520
-30% -$1.23M
EPRX
16
Eupraxia Pharmaceuticals
EPRX
$408M
$2.55M 1.6%
352,000
– –
CTMX icon
17
CytomX Therapeutics
CTMX
$766M
$2.54M 1.59%
540,000
+460,000
+575% +$2.33M
VRCA icon
18
Verrica Pharmaceuticals
VRCA
$94.3M
$2.49M 1.56%
471,559
– –
JSPR icon
19
Jasper Therapeutics
JSPR
$27.1M
$2.34M 1.46%
2,668,395
– –
RZLT icon
20
Rezolute
RZLT
$429M
$2.29M 1.43%
750,000
– –
LYEL icon
21
Lyell Immunopharma
LYEL
$317M
$2.05M 1.28%
+102,000
New +$2.38M
PROF
22
Profound Medical
PROF
$247M
$1.85M 1.16%
285,710
– –
VRDN icon
23
Viridian Therapeutics
VRDN
$2.05B
$1.78M 1.12%
91,123
+4,623
+5% +$137K
RCKT icon
24
Rocket Pharmaceuticals
RCKT
$375M
$1.05M 0.66%
+294,643
New +$1.17M
KZIA
25
Kazia Therapeutics
KZIA
$155M
$1.01M 0.63%
135,315
-164,685
-55% -$1.15M
1
2 3

Similar funds

BBA
Braun-Bostich & Associates Canonsburg, Pennsylvania $160M AUM 17.77% 1-Year Est. Return
EFG
Erickson Financial Group Allentown, Pennsylvania $160M AUM 16.74% 1-Year Est. Return
CSA
Cornerstone Select Advisors St. Louis, Missouri $160M AUM 46.79% 1-Year Est. Return
BFAG
Blackston Financial Advisory Group The Villages, Florida $160M AUM 16.38% 1-Year Est. Return
FCM
Fairbanks Capital Management Rancho Santa Fe, California $160M AUM 14.36% 1-Year Est. Return
SLG
Sanchez Levi Garrett $159M AUM
PWM
Palacios Wealth Management Ormond Beach, Florida $160M AUM 37.98% 1-Year Est. Return
RFS
Richardson Financial Services Medway, Massachusetts $160M AUM 16.71% 1-Year Est. Return

Velan Capital Investment Management's Q1 2026 Portfolio in Review

As of Q1 2026, Velan Capital Investment Management held 57 positions worth $160M, down 7.4% from $172M the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Velan Capital Investment Management withdrew a net $14.4M in Q1 2026, closing 8 positions and reducing 7 holdings. Its most notable exit was Cidara Therapeutics, an estimated $23.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

Against the trend, Velan Capital Investment Management opened a new position in Anteris Technologies worth $3.88M.

  • Velan Capital Investment Management's largest Q1 2026 buy was Anteris Technologies: 700,000 shares worth $3.88M.
  • Velan Capital Investment Management added most to Tenax Therapeutics in Q1 2026, an estimated $6.76M increase.
  • Velan Capital Investment Management's biggest Q1 2026 reduction was Mineralys Therapeutics, cutting an estimated $4.11M.
  • Velan Capital Investment Management fully exited Cidara Therapeutics in Q1 2026, selling an estimated $23.9M.
  • Velan Capital Investment Management's ten largest holdings make up 73% of its $160M portfolio in Q1 2026.
  • Velan Capital Investment Management opened 11 new positions and closed 8 in Q1 2026.
  • Velan Capital Investment Management's portfolio value fell 7.4% quarter-over-quarter to $160M.

Based on Velan Capital Investment Management's 13F filing for Q1 2026, filed 15 May 2026.